PARIKH, ANKURKUMAR A – Trademark Portfolio
Entity Type: 01
PARIKH, ANKURKUMAR A holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 4 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include CAREMAX PHARMACY, R CAREMAX PHARMACY, and 15 MINUTE RX PHARMACY. The owner is based in SAINT JOHNS, FL.
SAINT JOHNS, FL 32259
Showing of trademarks Trademarks
Trademark Classifications
PARIKH, ANKURKUMAR A's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PARIKH, ANKURKUMAR A have?
PARIKH, ANKURKUMAR A has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 abandoned.
What trademark classes does PARIKH, ANKURKUMAR A file in?
PARIKH, ANKURKUMAR A files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are PARIKH, ANKURKUMAR A's most well-known trademarks?
PARIKH, ANKURKUMAR A's registered trademark portfolio includes well-known marks such as CAREMAX PHARMACY, R CAREMAX PHARMACY, and 15 MINUTE RX PHARMACY. These are among 4 currently registered trademarks in the portfolio.
What is PARIKH, ANKURKUMAR A's trademark registration success rate?
PARIKH, ANKURKUMAR A has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.